IGF-1 LR3 1mg

Introduction and Research Disclaimer

Insulin-like Growth Factor-1 Long R3 (IGF-1 LR3) is a recombinant analogue of human IGF-1 specifically engineered for enhanced biological potency and IGF-binding protein (IGFBP) independence. This product is supplied as a sterile, lyophilized powder containing 1mg of IGF-1 LR3 per vial, purified to pharmaceutical research-grade specifications exceeding 98% purity as determined by reversed-phase HPLC and mass spectrometry. This product is furnished exclusively for in vitro laboratory research and experimental model studies. It is not for human or veterinary therapeutic use, not for diagnostic procedures, and not for human consumption under any circumstances. Researchers handling this material must operate within institutional biosafety protocols and all applicable national and regional regulations governing the use of recombinant peptide analogues in laboratory settings. Biosim Peptides makes no representation regarding the suitability of this product for any purpose beyond controlled laboratory experimentation.

Molecular Overview and Structural Characteristics

IGF-1 LR3 is an 83-amino acid polypeptide with a molecular weight of approximately 9.1 kDa. The molecule represents a strategically engineered variant of wild-type human IGF-1 (70 amino acids, ~7.6 kDa) incorporating two key structural modifications that fundamentally alter its pharmacological profile. The primary modification is a single amino acid substitution at position 3 of the mature IGF-1 sequence, where the native glutamate (Glu) residue is replaced by arginine (Arg). This Glu3→Arg substitution resides within the B-domain of the IGF-1 molecule, a region critical for IGFBP recognition and binding. The second modification is a 13-amino acid N-terminal extension peptide (Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn) derived from a porcine growth hormone fusion partner utilized during recombinant expression in Escherichia coli systems. Together, these modifications reduce the affinity of IGF-1 LR3 for all six human IGFBPs (IGFBP-1 through IGFBP-6) by approximately 100- to 1,000-fold compared to native IGF-1, while preserving near-wild-type binding affinity for the type 1 IGF receptor (IGF-1R) with a Kd in the sub-nanomolar range. The N-terminal extension is not cleaved during purification, yielding a homogeneous product with precisely defined mass and sequence. The theoretical isoelectric point (pI) of IGF-1 LR3 is approximately 9.0, reflecting the addition of the positively charged arginine residue. The lyophilized powder is hygroscopic and must be stored at -20°C in a desiccated environment to maintain structural integrity. Upon reconstitution in appropriate buffer systems (typically 10mM acetic acid or 10mM HCl followed by dilution into phosphate-buffered saline or cell culture medium), the peptide adopts the characteristic insulin-like tertiary fold comprising three alpha-helical segments stabilized by three intramolecular disulfide bonds (Cys6-Cys48, Cys18-Cys61, and Cys47-Cys52), which are essential for receptor recognition and biological activity.

Mechanism of Action and Pharmacodynamic Distinctions

The biological actions of IGF-1 LR3 are mediated primarily through high-affinity binding to the IGF-1 receptor (IGF-1R), a heterotetrameric (α2β2) transmembrane receptor tyrosine kinase belonging to the insulin receptor family. Ligand engagement induces receptor autophosphorylation at key tyrosine residues within the intracellular kinase domain (Tyr1131, Tyr1135, Tyr1136 of the β-subunit), triggering recruitment of insulin receptor substrate (IRS) adaptor proteins—predominantly IRS-1 and IRS-2—and subsequent activation of two major downstream signaling cascades: the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the Ras/mitogen-activated protein kinase (MAPK) pathway. PI3K/Akt signaling drives protein synthesis via mTORC1-mediated phosphorylation of p70 S6 kinase and 4E-BP1, promotes glucose uptake through GLUT4 translocation, and suppresses proteolysis through FoxO transcription factor inactivation. The MAPK/ERK pathway contributes to cellular proliferation and differentiation through transcriptional regulation of cyclins and other cell-cycle regulatory proteins. What distinguishes IGF-1 LR3 mechanistically from native IGF-1 is its functional independence from the IGFBP system. In physiological contexts, over 99% of circulating IGF-1 is sequestered within ternary complexes comprising IGF-1, IGFBP-3 (or IGFBP-5), and the acid-labile subunit (ALS), which collectively restrict IGF-1 bioavailability, limit transendothelial transport, and extend circulating half-life to approximately 12-15 hours. IGF-1 LR3, by virtue of its profoundly reduced IGFBP affinity, remains unsequestered and fully bioavailable in experimental systems, even in the presence of supraphysiological concentrations of binding proteins. This property confers several experimentally relevant advantages: enhanced tissue penetrance in three-dimensional culture systems and organoid models, sustained receptor activation kinetics in the presence of IGFBPs secreted by cultured cells, and simplified dose-response relationships unconfounded by variable binding-protein concentrations across experimental replicates. IGF-1 LR3 also exhibits weak cross-reactivity with the insulin receptor (IR-A and IR-B isoforms), though at affinities approximately 100- to 500-fold lower than for IGF-1R, which should be considered when interpreting experiments conducted at high nanomolar to micromolar concentrations.

Research Applications in Laboratory Science

IGF-1 LR3 has been deployed across a broad spectrum of in vitro and ex vivo research applications where IGFBP-independent IGF-1R activation is experimentally desirable. In skeletal muscle cell biology, IGF-1 LR3 is utilized to dissect the relative contributions of IGF-1R-mediated anabolic signaling versus IGFBP-mediated modulation in myoblast proliferation (C2C12 and L6 cell lines), myotube hypertrophy, and the regulation of myogenic regulatory factors including MyoD, myogenin, and MRF4. The compound’s IGFBP independence renders it particularly valuable in conditioned media experiments where endogenous IGFBP secretion by differentiating myotubes would otherwise confound interpretation of native IGF-1 dose-response studies. In intestinal epithelial research, IGF-1 LR3 has been employed in organoid and enteroid models (including human duodenal and colonic organoids) to investigate IGF-1R-dependent crypt cell proliferation, villus morphogenesis, and epithelial barrier function without interference from IGFBPs present in Matrigel or other basement membrane extracts. In neurobiology, the analogue has been applied to primary neuronal cultures, neural stem cell expansion protocols, and ex vivo brain slice preparations to examine IGF-1R-mediated neuroprotection against excitotoxic, oxidative, and hypoxic insults, and to probe the role of IGF signaling in hippocampal neurogenesis and synaptic plasticity paradigms. Additional areas of active investigation include chondrocyte and osteoblast biology—where IGF-1 LR3 is used to study growth plate dynamics and bone matrix deposition in the absence of IGFBP-3 and IGFBP-5 sequestration; wound healing and dermal fibroblast models examining IGF-1R-dependent keratinocyte migration and collagen synthesis; and comparative receptor pharmacology studies employing IGF-1 LR3 alongside IGF-1, IGF-2, insulin, and receptor-specific monoclonal antibodies to map ligand-specific signaling bias at IGF-1R, IR-A, IR-B, and hybrid receptors.

Key Research Studies and Literature Findings

The foundational characterization of IGF-1 LR3 was established by Francis and colleagues (PMID 1380453), who demonstrated through competitive binding assays that the Glu3Arg substitution combined with the N-terminal extension reduced IGFBP-1 and IGFBP-3 affinity by approximately 200- to 500-fold while preserving full IGF-1R binding and receptor autophosphorylation capacity in L6 myoblast and NIH-3T3 fibroblast models. Tomas and coworkers (PMID 7683275) subsequently confirmed the enhanced anabolic potency of IGF-1 LR3 in skeletal muscle systems, reporting that the analogue stimulated protein synthesis and inhibited proteolysis in incubated rat epitrochlearis and soleus muscles with approximately 2- to 3-fold greater potency than equimolar native IGF-1, an effect attributable to its evasion of endogenous IGFBPs released into the incubation medium. Steeb and associates (PMID 7505536) extended these observations to the gastrointestinal system, demonstrating that chronic subcutaneous administration of IGF-1 LR3 to rats produced significantly greater increases in small intestinal length, mucosal mass, and crypt cell proliferation than equivalent doses of native IGF-1, findings that have informed subsequent organoid and tissue-engineering applications. Loddick and colleagues (PMID 8612667) reported that displacement of endogenous IGF-1 from IGFBPs—a pharmacological effect mimicked by IGF-1 LR3 administration—produced neuroprotective effects in rodent models of focal cerebral ischemia, highlighting the biological significance of the IGFBP reservoir in neural injury contexts. These seminal findings established the research paradigm in which IGF-1 LR3 serves as a molecular tool to experimentally isolate IGFBP-dependent from IGFBP-independent IGF-1R signaling effects.

Handling, Reconstitution, and Storage Protocols

Proper handling of IGF-1 LR3 is essential to preserve peptide integrity and ensure experimental reproducibility. Upon receipt, lyophilized vials should be inspected for cake integrity and immediately stored at -20°C in a desiccated, light-protected environment. The lyophilized peptide is stable for a minimum of 24 months under these conditions. Reconstitution must be performed under aseptic conditions in a certified biosafety cabinet using sterile, low-retention pipette tips to minimize adsorptive losses. IGF-1 LR3 is sparingly soluble in neutral aqueous buffers; initial reconstitution should be performed in 10mM acetic acid (pH 3.0-3.5) or 10mM hydrochloric acid at a concentration of 0.5-1.0 mg/mL, with gentle swirling to dissolve the cake completely—vortex mixing should be avoided as it may induce aggregation and precipitation. Once fully dissolved, the stock solution may be diluted into sterile phosphate-buffered saline (PBS), HEPES-buffered saline, or serum-free cell culture medium to the desired working concentration. Reconstituted stock solutions stored at 4°C should be used within 7 days, while aliquots stored at -80°C in siliconized or low-protein-binding microcentrifuge tubes remain stable for up to 6 months. Repeated freeze-thaw cycles must be avoided; single-use aliquots are strongly recommended. For cell culture applications, IGF-1 LR3 is typically employed at concentrations ranging from 1 ng/mL to 200 ng/mL (approximately 0.1-22 nM), with most anabolic and proliferative endpoints observed in the 10-100 ng/mL range. Researchers should include vehicle-only controls (matching acetic acid or HCl concentration) and native IGF-1 comparator conditions in all experimental designs to control for solvent effects and to benchmark IGFBP-dependent versus IGFBP-independent signaling.

Safety and Laboratory Precautions

Although IGF-1 LR3 is supplied exclusively for research use, prudent laboratory safety practices must be observed during all handling procedures. Personal protective equipment including nitrile gloves, laboratory coat, and safety glasses should be worn at all times. All reconstitution and aliquot preparation should be conducted in a Class II biological safety cabinet. The lyophilized powder should be treated as a potential respiratory irritant; weighing and transfer operations should be performed in a fume hood or biosafety cabinet with appropriate dust-containment measures. In the event of skin contact, the affected area should be washed immediately with copious amounts of soap and water. Eye exposure requires irrigation with sterile saline or water for a minimum of 15 minutes and medical consultation. Spills should be contained with absorbent material, decontaminated with 70% ethanol or 1% sodium hypochlorite solution, and disposed of in accordance with institutional chemical waste protocols. The acute toxicity profile of IGF-1 LR3 in experimental models indicates a wide safety margin; however, the compound is a potent mitogenic and anabolic signaling molecule, and its effects on transformed or immortalized cell lines—particularly those with amplified or constitutively active IGF-1R signaling—should be evaluated carefully in the context of each experimental system. Researchers are advised to consult their institutional biosafety committee regarding appropriate biosafety level classification for experiments involving IGF-1 LR3, particularly in protocols involving viral transduction or genetic modification of IGF-1R pathway components.

Frequently Asked Questions

Q: What is the primary functional advantage of IGF-1 LR3 over native IGF-1 in cell culture experiments?
A: The defining advantage is its independence from IGF-binding proteins (IGFBPs). Most cultured cell types secrete IGFBPs into conditioned medium, which sequester native IGF-1 and reduce its effective free concentration in nonlinear, time-dependent, and cell-density-dependent ways. IGF-1 LR3 exhibits 100- to 1,000-fold reduced affinity for all six human IGFBPs, yielding predictable and reproducible receptor activation kinetics regardless of endogenous IGFBP secretion. This simplifies dose-response analyses and improves inter-experiment reproducibility, particularly in long-term culture protocols exceeding 48 hours where IGFBP accumulation becomes significant.

Q: Can IGF-1 LR3 be used interchangeably with native IGF-1 in standard protocols?
A: Not without careful validation. While both ligands engage IGF-1R with comparable affinity, their differential interaction with IGFBPs means that equimolar concentrations produce different free ligand concentrations in IGFBP-containing systems. In serum-free, IGFBP-depleted systems they may produce comparable effects, but in serum-containing or conditioned media experiments, IGF-1 LR3 will typically exhibit greater apparent potency. Cross-reactivity at the insulin receptor is slightly elevated for IGF-1 LR3 at very high concentrations (above 500 nM), and researchers should include appropriate insulin receptor antagonist controls when interpreting results at these concentrations.

Q: What is the recommended reconstitution and storage protocol for maximum peptide stability?
A: Reconstitute in 10mM acetic acid (pH ~3.0) at 0.5-1.0 mg/mL. Avoid neutral buffers for initial reconstitution as the peptide is poorly soluble near its isoelectric point (~pH 9.0) or in phosphate buffers. Do not vortex. Once dissolved, dilute into working buffer. Store stock aliquots at -80°C in low-protein-binding tubes for up to 6 months. Avoid repeated freeze-thaw cycles. Working dilutions at 4°C should be used within 7 days. The lyophilized powder is stable at -20°C for at least 24 months.

Q: Is IGF-1 LR3 suitable for use in in vivo experimental models?
A: IGF-1 LR3 has been employed in numerous peer-reviewed rodent studies investigating muscle hypertrophy, intestinal adaptation, and neuroprotection. However, its use in any whole-organism model requires prior approval from the relevant institutional animal care and use committee (IACUC) or equivalent ethical review body. Researchers should be aware that the extended in vivo half-life of IGF-1 LR3 compared to native IGF-1 (due to reduced clearance via the renal-IGFBP pathway) may necessitate adjustments to dosing frequency relative to native IGF-1 protocols. All such research must be conducted in strict compliance with applicable animal welfare regulations.

Q: How should I validate IGF-1 LR3 activity in my experimental system?
A: The gold standard for activity validation is IGF-1R autophosphorylation analysis by Western blot using phospho-specific antibodies targeting Tyr1131 or Tyr1135/1136 of the IGF-1R β-subunit. Downstream readouts include phospho-Akt (Ser473), phospho-S6 (Ser235/236), and phospho-ERK1/2 (Thr202/Tyr204). A dose-response curve (typically 0.1-100 ng/mL in serum-starved cells, 15-30 minute stimulation) should be generated for each cell type. Viability and proliferation assays (MTT, BrdU incorporation) should be used to confirm biologically relevant concentration ranges. Parallel testing with native IGF-1 is recommended to benchmark IGFBP-dependent versus independent signaling in your specific model.

References

1. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Endocrinology. 1992;134(2):287-295. PMID: 1380453.
2. Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in rats. Journal of Endocrinology. 1993;137(1):69-80. PMID: 7683275.
3. Steeb CB, Trahair JF, Tomas FM, Read LC. Prolonged administration of IGF-I and IGF-I long R3 to rats increases small intestinal length. American Journal of Physiology. 1994;266(6 Pt 1):G1090-G1098. PMID: 7505536.
4. Loddick SA, Liu XJ, Lu ZX, et al. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proceedings of the National Academy of Sciences USA. 1998;95(4):1894-1898. PMID: 8612667.
5. Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC. Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochemical and Biophysical Research Communications. 1993;190(3):846-853. PMID: 1312582.
6. Cohick WS, Clemmons DR. The insulin-like growth factors. Annual Review of Physiology. 1993;55:131-153. PMID: 7682045.